Health & Fitness
Health and Fitness
Health and Fitness 
Wed, May 11, 2011
Abiomed Announces PROTECT II Study Data Will Be Presented at EuroPCR 2011 in Late-Breaking Clinical Trial Session
DANVERS, Mass.--([ BUSINESS WIRE ])--[ Abiomed Inc ]. (NASDAQ: ABMD), a leading provider of [ breakthrough heart support technologies ], today announced that data from the PROTECT II study will be presented by Jeffrey W. Moses, M.D., Director of Interventional Services at NewYork-Presbyterian Hospital/Columbia University - Cornell Medical Center, during the late-breaking registries and clinical trial update session at EuroPCR 2011 in Paris.
"PROTECT II: A Prospective Multicenter Trial Comparing Impella to Intra-Aortic Balloon Pump in High-Risk PCI"
The presentation, aPROTECT II: A Prospective Multicenter Trial Comparing Impella to Intra-Aortic Balloon Pump in High-Risk PCIa is scheduled for Friday, May 20, between 9:10 a.m. a" 12:10 p.m. CEST in Room 342AB at the Palais des Congres de Paris.
PROTECT II was a prospective multicenter randomized clinical trial of Impella versus the intra-aortic balloon pump for hemodynamic support during high- risk percutaneous coronary intervention (PCI).
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: [ www.abiomed.com ].
FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recent Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.